Research Brief
Retatrutide: Chemical Properties
17 Citacoes PubMedRevisado por EspecialistasCertificado GMPUltima Revisao: julho de 2026
Propriedades Quimicas
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4731.33 Da |
| CAS Number | 2381089-83-2 |
| PubChem CID | 171390338 |
| Sequence (1-Letter) | Y-Aib-QGTFTSDYSI-αMeL-LDK-K*-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂ (* = Lys modified with AEEA-γGlu-C20 diacid) |
| Sequence (3-Letter) | Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
| Structure | 39-aminoacido linear peptide; GIP backbone; non-coded residues: Aib at positions 2 & 20, α-methyl-L-leucine at position 13; C20 fatty diacid conjugated at Lys-17 via AEEA-γGlu linker; C-terminus amidated |
| Origin | Synthetic peptide engineered from GIP (dependente de glicose insulinotropic polypeptide) backbone; developed by Eli Lilly and Company |
| Classification | Triple Incretin/Hormone Receptor Agonist (GLP-1/GIP/Glucagon) / Acylated Peptide / Investigational Drug |
| Half-Life | Aproximadamente 6 days in humans, supporting once-dosagem semanal |
| Bioavailability | Subcutaneous injection; Tmax 12–72 hours; albumin binding via C20 fatty diacid extends duration of action |
Identificadores
| Purity Standard | ≥99% by RP-HPLC (research grade) |
| Synonyms | Retatrutide, LY3437943, LY-3437943, RTT, GGG Tri-Agonist, Triple G, Triple Agonist, Reta Peptide |
| InChI Key | MLOLQJNKXBNWFW-JMUPIODPSA-N |
| Developer | Eli Lilly and Company (Indianapolis, IN, USA) |
Referencias
- Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526, 2023.
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon agonista do receptor, for people with diabetes tipo 2: a randomised, duplo-cego, placebo and active-controlled, parallel-group, phase 2 trial conducted no(a) USA. Lancet, 402(10401), 529-544, 2023.
- Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone agonista do receptor retatrutide for metabolic dysfunction-associated steatotic doenca hepatico(a)a: a randomizado phase 2a trial. Nature Medicine, 30(7), 2037-2048, 2024.
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, um(a) novo(a) triple glucagon, GIP, and GLP-1 agonista do receptor for glycemic control and perda de peso: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9, 2022.
- Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for o tratamento of obesidade, obstructive sleep apnea and knee osteoartrite: Rationale and design do(a) TRIUMPH registrational ensaios clinicos. Diabetes, Obesity and Metabolism, 28(1), 83-93, 2026.
- Coskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on composicao corporal in people with diabetes tipo 2: a substudy of a phase 2, duplo-cego, parallel-group, controlado por placebo, randomised trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684, 2025.
- Heerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A, Hartman ML. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports, 10(6), 1980-1992, 2025.
- Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, um(a) novo(a) triple GIP, GLP-1, and glucagon agonista do receptor in people with diabetes tipo 2: a phase 1b, multicentre, duplo-cego, controlado por placebo, randomised, multiplos(as)-ascending dose trial. Lancet, 400(10366), 1869-1881, 2022.
- Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and caracteristicas basais do(a) TRANSCEND-CKD trial of retatrutide in patients with cronico(a) doenca renal. Nephrology Dialysis Transplantation, gfaf230, 2025.
- Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide - A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796, 2025.
- Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide's role in modern obesidade and diabetes therapy. European Journal of Pharmacology, 985, 177095, 2024.
- Maharshi V, Singh S, Manjhi PK, Singh SK, Kumar A, Kumar R. Navigating retatrutide safety: comprehensive insights from revisao sistematica and meta-analise. Journal of Public Health and Development, 24(1), 318-338, 2026.
- Abouelmagd AA, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM. Efficacy and safety of retatrutide, um(a) novo(a) GLP-1, GIP, and glucagon agonista do receptor for obesidade treatment: a revisao sistematica and meta-analise of randomizado controlled trials. Proceedings (Baylor University Medical Center), 38(3), 291-303, 2025.
- Marathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesidade-associated cancer progression. NPJ Metabolic Health and Disease, 3(1), 10, 2025.
- Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of o efeitos of Liraglutide, Tirzepatide, and Retatrutide on diabetic doenca renal in db/db mice. Endocrine, 87(1), 159-169, 2025.
- Tewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, Maheshwari A. Efficacy and safety of triple hormone agonista do receptor retatrutide para o(a) management of obesidade: a revisao sistematica and meta-analise. Expert Review of Clinical Pharmacology, 18(1-2), 51-66, 2025.
- Urva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T. The novel GIP, GLP-1 and glucagon agonista do receptor retatrutide retarda gastric emptying. Diabetes, Obesity and Metabolism, 25(11), 2784-2788, 2023.
Perguntas de Pesquisa Relacionadas
APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.